Jeremy R. Graff


Director

Dr. Jeremy Graff has served as a member of our board of directors since May 2023. With over two decades of experience in drug development and leadership within the biotechnology and pharmaceutical sectors, Dr. Graff currently serves as the Chief Scientific Officer at IMV Inc, an early-stage Canadian biotechnology company. There, he oversees the company’s research programs and the development of its cutting-edge cancer vaccine platform. Previously, Dr. Graff held C-level and senior executive positions at various biotechnology companies. During his nearly 17-year tenure at Eli Lilly and Company, Dr. Graff identified and validated new molecular targets for advanced cancers, working alongside the clinical development team to establish and lead the translational oncology group. This group supported and advanced the 31 clinical assets in Eli Lilly’s oncology portfolio at the time. Dr. Graff also serves as a member of the Board of Trustees for the Wood Hudson Cancer Research Laboratory and is on the Scientific Advisory Board of Avicenna Biosciences, Inc. He completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.